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Abstract
Bioactive oxidized linoleic acid metabolites (OXLAMs) include 13- and 9-hydroxy-octadecadienoic acid (13-
HODE + 9-HODE) and have been linked to oxidative stress, inflammation, and numerous pathological and 
physiological states. The purpose of this study was to measure changes in plasma 13-HODE + 9-HODE 
following a 75-km cycling bout and identify potential linkages to linoleate metabolism and established 
biomarkers of oxidative stress (F2-isoprostanes) and inflammation (cytokines) using a metabolomics approach. 
Trained male cyclists (N � 19, age 38.0 + 1.6 yr, wattsmax 304 +10.5) engaged in a 75-km cycling time trial on 
their own bicycles using electromagnetically braked cycling ergometers (2.71 + 0.07 h). Blood samples were 
collected preexer-cise, immediately post-, 1.5 h post-, and 21 h postexercise, and analyzed for plasma cytokines 
(IL-6, IL-8, IL-10, tumor necrosis factor-�, monocyte chemoattractant protein-1, granulocyte colony-
stimulating factor), F2-isoprostanes, and shifts in metabolites using global metabolomics procedures with gas 
chromatography mass spec-trometry (GC-MS) and liquid chromatography mass spectrometry (LC-MS). 13-
HODE +9-HODE increased 3.1-fold and 1.7-fold immediately post- and 1.5 h postexercise (both P <0.001) and 
returned to preexercise levels by 21-h postexercise. Post-75-km cy-cling plasma levels of 13-HODE � 9-HODE 
were not significantly correlated with increases in plasma cytokines but were positively correlated with 
postexercise F2-isoprostanes (r =0.75, P < 0.001), linoleate (r = 0.54, P = 0.016), arachidate (r = 0.77, P < 0.001), 
12,13-dihydroxy-9Z-octadecenoate (12,13-DiHOME) (r = 0.60, P = 0.006), dihomo-linolenate (r =0.57, P = 
0.011), and adrenate (r = 0.56, P = 0.013). These findings indicate that prolonged and intensive exercise caused 
a transient, 3.1-fold increase in the stable linoleic acid oxidation product 13-HODE + 9-HODE and was related 
to increases in F2-isoprostanes, linoleate, and fatty acids in the linoleate conver-sion pathway. These data 
support the use of 13-HODE + 9-HODE as an oxidative stress biomarker in acute exercise investigations
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Bioactive oxidized linoleic acid metabolites (OXLAMs) include 
13- and 9-hydroxy-octadecadienoic acid (13-HODE + 9-HODE) and 
have been linked to oxidative stress, inflammation, and numerous 
pathological and physiological states. The purpose of this study 
was to measure changes in plasma 13- HODE + 9-HODE 
following a 75-km cycling bout and identify potential linkages to 
linoleate metabolism and established biomarkers of oxidative stress 
(F2-isoprostanes) and inflammation (cytokines) using a 
metabolomics approach. Trained male cyclists (N = 19, age 
38.0 ± 1.6 yr, wattsmax 304 ± 10.5) engaged in a 75-km cycling time 
trial on their own bicycles using electromagnetically braked cycling 
ergometers (2.71 ± 0.07 h). Blood samples were collected preexer- 
cise, immediately post-, 1.5 h post-, and 21 h postexercise, and 
analyzed for plasma cytokines (IL-6, IL-8, IL-10, tumor necrosis 
factor-ex, monocyte chemoattractant protein-1, granulocyte colony- 
stimulating factor), F2-isoprostanes, and shifts in metabolites using 
global metabolomics procedures with gas chromatography mass spec- 
trometry (GC-MS) and liquid chromatography mass spectrometry 
(LC-MS). 13-HODE + 9-HODE increased 3.1-fold and 1.7-fold 
immediately post- and 1.5 h postexercise (both P < 0.001) and 
returned to preexercise levels by 21-h postexercise. Post-75-km cy- 
cling plasma levels of 13-HODE + 9-HODE were not significantly 
correlated with increases in plasma cytokines but were positively 
correlated with postexercise F2-isoprostanes (r = 0.75, P < 0.001), 
linoleate (r = 0.54, P = 0.016), arachidate (r = 0.77, P < 0.001), 
12,13-dihydroxy-9Z-octadecenoate (12,13-DiHOME) (r = 0.60, P = 
0.006), dihomo-linolenate (r = 0.57, P = 0.011), and adrenate (r = 
0.56, P = 0.013). These findings indicate that prolonged and intensive 
exercise caused a transient, 3.1-fold increase in the stable linoleic acid 
oxidation product 13-HODE + 9-HODE and was related to increases 
in F2-isoprostanes, linoleate, and fatty acids in the linoleate conver- 
sion pathway. These data support the use of 13-HODE + 9-HODE as 
an oxidative stress biomarker in acute exercise investigations. 
exercise; oxidative stress; inflammation; linoleate; metabolites 
THE RATE OF WHOLE BODY and muscle oxygen consumption 
increases during acute, high-intensity, and continuous exercise 
bouts and is accompanied by an increase in production of 
reactive oxygen species (ROS) (8, 26, 27). The causes of 
increased ROS during exercise include electron leakage in the 
mitochondrial electron transport chain, activation of neutro- 
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phils and other phagocytic cells, auto-oxidation of cat- 
echolamines, and activation of several enzymes including xan- 
thine oxidase, phospholipase A2, and nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidase (8). Direct measure- 
ment of free radical and ROS production is difficult, and 
assessment of oxidative stress during exercise is typically made 
using indirect methods (22). Reliable oxidative stress biomark- 
ers should be chemically unique and detectable, have relatively 
long half-lives, and be responsive to increases or decreases in 
ROS (26). The level of F2-isoprostanes (F2-IsoP) in blood or 
urine is widely regarded as an excellent indicator of exercise- 
induced oxidative stress and is formed via free radical-initiated 
peroxidation of arachidonic acid (22, 30). 
Linoleic acid (18:2n-6) is the most common polyunsaturated 
fatty acid (PUFA) in human diets and mammalian tissue and is 
considered essential because humans lack delta-12 and del- 
ta-15 desaturase enzymes (9, 15, 29, 33). Ingested linoleic acid 
is converted to longer and more unsaturated fatty acids through 
enzymatic desaturation and elongation in the endoplasmic 
reticulum of cells. Linoleic acid is the direct precursor to 
oxidized linoleic acid metabolites (OXLAMs) including 13- 
and 9-hydroxy-octadecadienoic acid (13-HODE + 9-HODE) 
(9, 15, 29, 33) (see http://www.genome.jp/kegg-bin/show_ 
pathway?map00591 for more detail). 13-HODE + 9-HODE 
are stable oxidation products and have been linked to patho- 
logical conditions including atherosclerosis, diabetes, Alzhei- 
mer’s disease, non-alcoholic steatohepatitis, psoriasis, chronic 
inflammation, obesity, and cancer (14, 23, 29, 37). Plasma 
levels of 13-HODE + 9-HODE are responsive to lifestyle 
interventions, with decreases reported when subjects adopt 
healthy diets and lose excess body weight (2, 3, 7, 25). 13-
HODE + 9-HODE are generated through the 15-lipoxy- 
genase-1 (15-LOX) pathway in a variety of cell types (17, 25), 
are ligands of peroxisome proliferator-activated receptors 
(PPARs) (28), and can act through G protein-coupled receptor 
132 (GPR132) to exert pro-inflammatory effects (37). 
Little information has been published on the influence of 
exercise on plasma 13-HODE + 9-HODE, and whether 
postexercise increases relate to changes in established bio- 
markers of oxidative stress and inflammation (19, 20). Using a 
metabolomics approach, we recently reported that plasma 13- 
HODE + 9-HODE increased 5.5-fold in 15 runners following 
a 3-day period of intensified training (2.5 h/day running at 70% 
V̇ O2max), with levels returning to preexercise levels after 14-h 
recovery (20). Metabolomics allows the simultaneous mea- 
surement of hundreds of metabolites and is especially valuable 
when focusing on complex interactions within the body during 
exercise or nutrition interventions. The purpose of this study 
was to measure the effect of prolonged and intensive exercise 
on plasma 13-HODE + 9-HODE and linoleic acid metabolism 
and correlations with postexercise increases in plasma F2-IsoP 
and inflammatory cytokines. 
MATERIALS AND METHODS 
Subjects. Subjects included 19 male cyclists (ages 27– 49 yr) who 
regularly competed in road races (racing categories 1 to 5, with 5 
assigned to cyclists with the lowest performance ability and experi- 
ence) and were capable of cycling 75 km at race pace. Subjects trained 
normally, maintained weight, and avoided the use of large-dose 
vitamin and mineral supplements (above 100% Daily Value), and all 
herbal supplements and medications for the 2-wk period before the 
75-km cycling time trial. All subjects signed informed consent and all 
study procedures were approved by the Institutional Review Board at 
Appalachian State University. 
Research design. Two weeks before the 75-km time trial, athletes 
completed orientation and baseline testing in the North Carolina 
Research Campus Human Performance Laboratory operated by Ap- 
palachian State University in Kannapolis, NC. Demographic and 
training histories were acquired with questionnaires. Maximal power, 
oxygen consumption, ventilation, and heart rate were measured during 
a graded exercise test (25 Watts increase every 2 min, starting at 150 
Watts) with the Cosmed Quark CPET metabolic cart (Rome, Italy) 
and the Lode cycle ergometer (Lode Excaliber Sport, Lode, Gro- 
ningen, The Netherlands). Body composition was measured with 
the Bod Pod body composition analyzer (Life Measurement, Con- 
cord, CA). 
Two weeks after baseline testing, subjects returned to the Human 
Performance Laboratory at 6:45 AM in an overnight fasted state (no 
food or beverages other than water for at least 9 hours) and provided 
a preexercise blood sample. After warming up, subjects cycled on 
their own bicycles on CompuTrainer Pro model 8001 trainers (Rac- 
erMate, Seattle, WA) with heart rate and rating of perceived exertion 
(RPE) recorded every 30 min and workload continuously monitored 
using the CompuTrainer MultiRider software system (version 3.0, 
RacerMate, Seattle, WA). A mountainous 75-km course with moder- 
ate difficulty was chosen and programmed into the software system. 
Oxygen consumption and ventilation were measured using the 
Cosmed Quark CPET metabolic cart after 16 and 55 km cycling. 
Subjects were allowed to ingest water ad libitum during the 75-km 
cycling time trial, but not any other beverage or food containing 
energy or nutrients. Blood samples were taken via venipuncture 
immediately and 1.5 h after completing the 75-km time trial. Subjects 
returned in an overnight fasted state the next morning to provide a 
21-h postexercise blood sample. No dietary restrictions were imposed 
from 1.5-h postexercise to the beginning of the overnight fast. 
F2-isoprostanes. Plasma F2-IsoP were determined using gas chro- 
matography mass spectrometry (GC-MS) (18). Plasma was collected 
from heparinized blood, flash-frozen in liquid nitrogen, and stored at 
-80°C. Plasma samples were thawed, and free F2-IsoP was extracted 
with deuterated [2H4]prostaglandin F2ex added as an internal standard. 
Waters Sep-Pak C18 cartridges followed by Waters Sep-Pak Silica 
cartridges were used for solid phase extraction. F2-IsoP were con- 
verted to pentafluorobenzyl esters, subjected to thin layer chromatog- 
raphy, and converted to trimethylsilyl ether derivatives. Samples were 
analyzed by a negative ion chemical ionization GC-MS using an Agilent 
6890N gas chromatography interfaced to an Agilent 5975B inert MSD 
mass spectrometer (Agilent Technologies, Santa Clara, CA). 
Cytokines. Total plasma concentrations of six inflammatory cyto- 
kines [monocyte chemoattractant protein-1 (MCP-1), tumor necrosis 
factor-ex (TNF-ex), granulocyte colony-stimulating factor (GCSF), 
IL-6, IL-8, and IL-10] were determined using an electrochemilumi- 
nescence based solid-phase sandwich immunoassay (Meso Scale 
Discovery, Gaithersburg, MD). All samples and provided standards 
were analyzed in duplicate, and the intra-assay coefficient of variation 
(CV) ranged from 1.7% to 7.5% and the interassay CV 2.4 to 9.6% for 
all cytokines measured. Pre- and postexercise samples for the cyto- 
kines were analyzed on the same assay plate to decrease interkit assay 
variability. 
Metabolomics. The nontargeted metabolic profiling instrumenta- 
tion employed for this analysis combined three independent plat- 
forms: ultrahigh performance liquid chromatography/tandem mass 
spectrometry (UHPLC/MS/MS) optimized for basic species, UHPLC/ 
MS/MS optimized for acidic species, and GC/MS (1, 6). Blood 
samples were collected in EDTA tubes and centrifuged at 3,000 rpm 
for 10 min at 4°C, with the plasma aliquoted, snap frozen in liquid 
nitrogen, and stored at -80°C until analysis. For each plasma sample, 
100 µl was used for analyses. With the use of an automated liquid 
handler (Hamilton LabStar, Salt Lake City, UT), protein was precip- 
itated from the plasma with methanol that contained four standards to 
report on extraction efficiency. The resulting supernatant was split 
into equal aliquots for analysis on the three platforms. Aliquots, dried 
under nitrogen and vacuum desiccated, were subsequently either 
reconstituted in 50 µl 0.1% formic acid in water (acidic conditions) or 
in 50 µl 6.5 mM ammonium bicarbonate in water, pH 8 (basic 
conditions) for the two UHPLC/MS/MS analyses or derivatized to a 
final volume of 50 µl for GC/MS analysis using equal parts bistrim- 
ethyl-silyl-trifluoroacetamide and solvent mixture acetonitrile-dichlo- 
romethane-cyclohexane (5:4:1) with 5% triethylamine at 60°C for 1 h. 
In addition, three types of controls were analyzed in concert with the 
experimental samples: aliquots of a well-characterized human plasma 
pool served as technical replicates throughout the data set, extracted 
water samples served as process blanks, and a cocktail of standards 
spiked into every analyzed sample allowed instrument perfor- 
mance monitoring. Standards to monitor extraction were d6-cho- 
lesterol, fl and tridecanoic acid. A standard to 
monitor GC/MS derivatization was 2-tert-butyl-6-methylphenol 
(BHT). GC/MS standards to monitor GC and MS performance were 
C5-C18 alkylbenzenes. Experimental samples and controls were ran- 
domized across platform run days. Instrument variability was deter- 
mined by calculating the median relative standard deviation (RSD) for 
the internal standards that were added to each sample before injection 
into the mass spectrometers. Overall process variability was deter- 
mined by calculating the median RSD for all endogenous metabolites 
(i.e., noninstrument standards) present in technical replicates of 
MTRX3. Values for instrument (5%) and process variability (12%) 
met Metabolon’s acceptance criteria. 
For UHLC/MS/MS analysis, aliquots were separated using a Wa- 
ters Acquity UPLC (Waters, Millford, MA) instrument with separate 
acid/base-dedicated 2.1 mm X 100 mm Waters BEH C18 1.7-µm 
particle columns heated to 40°C, and analyzed using an LTQ mass 
spectrometer (Thermo Fisher Scientific, Waltham, MA), which con- 
sisted of an electrospray ionization (ESI) source and linear ion-trap 
(LIT) mass analyzer (6). Extracts reconstituted in formic acid were 
gradient eluted at 350 µl/min using 0.1% formic acid in water (A) and 
0.1% formic acid in methanol (B) (0% B to 70% B in 4 min, 70 –98% 
B in 0.5 min, 98% B for 0.9 min), whereas extracts reconstituted in 
ammonium  bicarbonate  used  6.5  mM  ammonium  bicarbonate  in 
Table 1.  Subject characteristics 
Variable Means ± SE 
Age, yr 38.0 ± 1.6 
Height, m 1.81 ± 0.02 
Weight, kg 76.8 ± 2.3 
Body fat, % 14.0 ± 1.0 
Wattsmax 304 ± 10.5 
V̇ O2max, ml·kg-1·min-1 51.7 ± 1.4 
HRmax, beats/min 179 ± 2.5 
Training, km/wk 192 ± 18.0 
n = 19 subjects; V̇ O2max, maximal oxygen consumed; HR, heart rate. 
Table 2.  Average 75-km metabolic and performance data 
Variable Means ± SE 
Time, h 2.71 ± 0.07 
VO2, ml·kg-1·min-1 38.3 ± 1.2 
VO2,%VO2max 69.3 ± 2.1 
Watts 207 ± 7.6 
% Wattsmax 68.3 ± 1.7 
HR, beats/min 150 ± 2.5 
%HRmax 84.0 ± 1.1 
Ventilation, l/min 74.9 ± 3.5 
RPE 12.9 ± 0.3 
VO2, volume of oxygen consumed; RPE, rating of perceived exertion. 
water, pH 8 (A) and 6.5 mM ammonium bicarbonate in 95/5 metha- 
nol-water (B) (same gradient profile as above) at 350 µl/min. The MS 
instrument scanned 99 –1,000 molecular weight (m/z) and alternated 
between MS and MS2 scans using dynamic exclusion with approxi- 
mately 6 scans per second. Derivatized samples for GC/MS were 
separated on a 5% diphenyl-95% dimethyl polysiloxane-fused silica 
column with helium as the carrier gas and a temperature ramp from 
60°C to 340°C and then analyzed on a Thermo-Finnigan Trace DSQ 
MS (Thermo Fisher Scientific) operated at unit mass resolving power 
with electron impact ionization and a 50- to 750-atomic mass unit 
scan range. Metabolites were identified by automated comparison of 
the ion features in the experimental samples to a reference library of 
chemical standard entries that included retention time, molecular 
weight (m/z), preferred adducts, and in-source fragments as well as 
associated MS spectra, and were curated by visual inspection for 
quality control using software developed at Metabolon (Durham, NC) 
(4). Common and biologically abundant isomers of unsaturated fatty 
acids containing the n3, n6, and n9 configuration are contained in 
Metabolon’s chemical standard library. Liquid chromatography mass 
spectrometry (LC-MS) standards to monitor LC and MS performance 
were d3-leucine, chloro- and bromo-phenylalanine, d2-maleic acid, 
amitriptyline, and d10-benzophenone (1). Biochemical identifications 
were based on three criteria: retention index within a narrow window 
of the proposed identification, accurate mass match to the library +/- 
0.005 amu, and the MS/MS forward and reverse scores between the 
experimental data and authentic standards. The MS/MS scores were 
based on a comparison of the ions present in the experimental 
spectrum to the ions present in the library spectrum. 
Statistical analysis. Data are expressed as means ± SE. For the 
metabolomics statistical analyses and data display purposes, any 
missing values were assumed to be below the limits of detection and 
these values were imputed with the compound minimum (minimum 
value imputation). Statistical analysis of log-transformed data was 
performed using “R” (R Foundation, from http://cran.r-project.org/), 
which is a freely available, open-source software package. One-way 
ANOVA with post hoc contrasts (t-tests) was performed to compare 
data across time points. An estimate of the false discovery rate (q 
value) was calculated to take into account the multiple comparisons 
that normally occur in metabolomic-based studies, with q < 0.05 used 
as an indication of high confidence in a result (34). Fold changes 
across time points were calculated using group averages of the median 
scaled intensity values. Plasma cytokines and F2-IsoP were analyzed 
using one-way ANOVA with post hoc contrasts (t-tests) performed to 
compare data across time points. Correlations between 13-HODE + 
9-HODE and other variables were made using Pearson’s product- 
moment correlation coefficients. 
RESULTS 
Subjects included 19 competitive male cyclists (ages 27 to 
49 yr) who successfully adhered to all aspects of the study 
design (see Table 1). Metabolic and performance data from the 
75-km mountainous cycling time trial are summarized in Table 2. 
The cyclists were able to maintain a high power output (69% 
Wattsmax) during the 75-km trial, with an average duration 
of 2.71 h. 
The metabolomics analysis revealed 423 detectable com- 
pounds of known identity. After log transformation and impu- 
tation with minimum observed values for each compound, 
repeated  measures  ANOVA  contrasts  identified  significant 
Pre-21 h-Post-75 km Pre-1.5 h-Post-75 km Pre-Post Exerc 
Fig. 1. Fold changes in metabolites grouped ac- 
cording to subpathways. Numbers in parentheses 
represent the number of metabolites in each sub- 
pathway that increased twofold or greater after the 
75-km cycling time trial. 
Nucleotide, purine (2) 
Carb metabolism (3) 
Kreb cycle (2) 
Hemoglobin (3) 
Carnitines (8) 
Amino acids (8) 
Sterol/steroid (1) 
Dihydroxy FA (2) 
Bile acid (2) 
Branched FA (2) 
Essential FA (7) 
Lipid Metabolism (2) 
Monohydroxy FA (5) 
Medium chain FA (4) 
Long chain FA (20) 
Dicarboxylate FA (7) 
Ketones (2) 
Fold Change 
Table 3. Exercise effects on linoleic acid and long chain polyunsaturated fatty acids in the conversion pathway (all time 
main effects, q < 0.001) 
Variable (Median Scaled Intensity) Preexercise Post-75 km 1.5-h Post-75 km 21-h Post-75 km 
Linoleate (18:2n6) 0.76 ± 0.06 2.86 ± 0.15* 
(3.7-fold) 
1.96 ± 0.11* 
(2.6-fold) 
0.83 ± 0.05 
Linolenate [ex or 'Y; (18:3n3 or 6)] 0.72 ± 0.07 4.23 ± 0.29* 
(5.8-fold) 
2.43 ± 0.20* 
(3.4-fold) 
0.76 ± 0.06 
Dihomo-linolenate (20:3n3 or n6) 0.77 ± 0.04 2.66 ± 0.16* 
(3.4-fold) 
2.18 ± 0.16* 
(2.8-fold) 
0.84 ± 0.04 
Arachidonate (20:4n6) 0.80 ± 0.06 1.83 ± 0.12* 
(2.3-fold) 
1.55 ± 0.08* 
(1.9-fold) 
0.84 ± 0.06 
Adrenate (22:4n6) 0.62 ± 0.08 2.13 ± 0.12* 
(3.4-fold) 
1.68 ± 0.17* 
(2.7-fold) 
0.78 ± 0.11 
Docosapentaenoate (22:5n6) 0.81 ± 0.06 1.59 ± 0.22* 
(2.0-fold) 
1.87 ± 0.18* 
(2.3-fold) 
0.94 ± 0.06 
Values are means ± SE. *P < 0.01 vs. preexercise. 
post-75 km cycling time effects for 221 metabolites. Fold 
changes were calculated from the median scaled intensity 
values for pre- to-post-75-km cycling time points and then rank 
ordered. A total of 80 metabolites of known identity had a 
twofold or higher increase following 75 km cycling (all q 
values <0.01). These were grouped by metabolic subpath- 
ways, and three mean fold changes were calculated (preexer- 
cise to immediately-, 1.5 h post-, and 21 h postexercise) (see 
Fig. 1 and Supplemental Table S1). All but 26 of these 
metabolites were related to lipid and carnitine metabolism, 
with the largest fold changes seen for ketones, dicarboxylate 
fatty acids, and long chain fatty acids. 
Table 3 summarizes exercise-induced changes in median 
scaled intensity (MSI) values for linoleic fatty acid (18:2n6) 
and five other long chain polyunsaturated fatty acids in the 
conversion pathway. Fold changes for all of these fatty acids 
ranged from 2.0 to 5.8 immediately post-75 km cycling and 1.9 
to 3.4 after 1.5 h recovery and were not different from preex- 
ercise after 21 h recovery. Plasma 13-HODE + 9-HODE 
increased 3.1- and 1.7-fold immediately and 1.5 h following 
the 75-km cycling time trial, respectively (time main effect, 
q < 0.001) (Fig. 2). Similar patterns of postexercise increases 
were seen for (Z)-9,10-dihydroxyoctadec-12-enoic acid (9,10- 
DiHOME)    and    (Z)-12,13-dihydroxyoctadec-9-enoic    acid 
13-HODE + 9-HODE 
3.0 
(12,13-DiHOME) (both time main effects, q < 0.001)(Fig. 3) 
and F2-IsoP (time main effect, P < 0.001) (Fig. 4). 
Plasma cytokine data are summarized in Table 4. Significant 
postexercise increases were measured for IL-6 (8.6-fold), IL-8 
(2.3-fold), IL-10 (9.1-fold), TNF-ex (1.10-fold), MCP-1 (1.44- 
fold), and GCSF (1.38-fold), with values near preexercise 
levels after 21 h recovery (all time main effects, P < 0.001). 
Immediate  postexercise  MSI  values  for  13-HODE  + 
9-HODE were significantly correlated with postexercise ara- 
chidonate (r = 0.77, P < 0.001), 12,13-DiHOME (r = 0.60, 
P = 0.006), and F2-IsoP (r = 0.75, P < 0.001) (Fig. 5, A–C). 
Postexercise 13-HODE + 9-HODE was also significantly 
correlated with postexercise linoleate (r = 0.54, P = 0.016), 
dihomo-linolenate (r = 0.57, P = 0.011), and adrenate 
(r=0.56, P = 0.013), and marginally to linolenate (r = 0.44, 
P = 0.058) and 9,10-DiHOME (r = 0.41, P = 0.081). Postex- 
ercise levels of 13-HODE + 9-HODE were not correlated with 
any of the postexercise cytokine concentrations listed in Table 
4. Immediate postexercise MSI values for linoleate were sig- 
nificantly correlated with 9,10-DiHOME (r = 0.64, P = 
0.003), 12,13-DiHOME (r = 0.58, P = 0.10), and each fatty 
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Pre-Exercise Post-75 km 1.5-h Post-75 km   21-h Post-75 km 
Fig. 2. Changes in  13- and 9-hydroxy-octadecadienoic  acid (13-HODE + 
9-HODE) across four time points: preexercise, immediately post-75-km cy- 
cling time trial, and 1.5-h and 21-h postexercise. *P < 0.01 compared with 
preexercise. Time main effect, P < 0.001. 
Fig. 3. Changes in (Z)-9,10-dihydroxyoctadec-12-enoic acid (9,10-DiHOME) 
and (Z)-12,13-dihydroxyoctadec-9-enoic acid (12,13-DiHOME) and across 
four time points: preexercise, immediately post-75-km cycling time trial, and 
1.5-h and 21-h postexercise. *P < 0.01 compared with preexercise. Time main 
effect, P < 0.001. 
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80 Oleic (18:1), palmitic (16:0), and linoleic (18:2) are the three 
major free fatty acids (FFA) in adipose tissue (9, 15). Upper 
70 body subcutaneous adipose tissue is the primary source of FFA 
during  prolonged  and  intensive  exercise  (11),  and  relative 
60 
availability is the predominant determinant of individual FFA 
50 use  by  contracting  muscles  (13).  Ketone  bodies  increased 
strongly in overnight fasted cyclists following the 75-km cy- 
40 cling time trial, indicating a high degree of FFA 13-oxidation. 
30 
20 
10 
0 
Pre-Exercise Post-75 km 1.5-h Post-75 km   21-h Post-75 km 
A  3.5
3 
2.5 
2 
Fig.  4.  Changes  in  F2-isoprostanes  across  four  time  points:  preexercise, 
immediately post-75-km cycling time trial, and 1.5-h and 21-h postexercise. 
*P < 0.01 compared with preexercise. Time main effect, P < 0.001.
acid listed in the conversion pathway except for docosapen- 
taenote (r = 0.32, P = 0.18; all other relationships, P < 0.02). 
DISCUSSION 
1.5 
1 
0.5 
0 
0 1 2 3 4 5 6 
Cyclists  experienced  a  transient  3.1-fold  increase  in  the 
oxidized linoleic acid derivative 13-HODE + 9-HODE follow- 
ing the 75-km cycling time trial. The postexercise increase in 
plasma concentration of HODEs was related to increases in the 
well-established oxidative stress biomarker, F2-IsoP, but not to 
increases  in  inflammatory  cytokines.  Postexercise  HODEs 
were also positively correlated with exercise-induced mobili- 
zation  of  most components of the linoleic acid conversion 
pathway including linoleate, dihomo-linolenate, arachidonate, 
and adrenate, and the oxidized isoleukotoxin 12,13-DiHOME. 
Metabolomics data revealed a twofold or greater postexer- 
cise increase in 80 metabolites of known identity, and two- 
thirds were related to lipid and carnitine metabolism. These 
results are very similar to those of our previous metabolomics- 
based investigation of 15 runners who ran 2.5 h/day at 70% 
V̇ O2max   3  days  in  a  row  (20).  Together,  these  two  studies 
indicate that following prolonged and intensive exercise, en- 
durance athletes experience profound systemic shifts in blood 
metabolites, especially those from the lipid pathway. In agree- 
ment with Lehman et al. (17), the data support substantial fatty 
acid transport across the mitochondrial membrane and oxida- 
tion during prolonged exercise. 
B  3.5
3 
2.5 
2 
1.5 
1 
0.5 
0 
C  160
140 
120 
100 
Post-Exercise 13-HODE + 9-HODE (MSI) 
0 1 2 3 4 5 6 
Post-Exercise 13-HODE + 9-HODE (MSI) 
80 
Table 4.  Exercise effects on plasma cytokines (all time main 
effects, P < 0.001) 60
Variable, 
pg/ml Preexercise Post-75 km 
1.5-h Post-75 
km 
21-h Post-75
40
km 
20 
IL-6 1.02 ± 0.28 8.77 ± 0.69* 5.97 ± 0.97* 0.63 ± 0.05 
IL-8 5.22 ± 0.42 11.83 ± 1.1* 7.91 ± 0.74* 4.70 ± 0.33 
IL-10 2.05 ± 0.21 18.6 ± 2.6* 10.6 ± 1.8* 2.14 ± 0.27 
TNF-ex 3.90 ± 0.16 4.30 ± 0.20* 4.10 ± 0.20 3.61 ± 0.16 
MCP-1 267 ± 9.1 385 ± 18.9* 340 ± 22.5* 230 ± 7.1 
GCSF 12.8 ± 1.0 17.7 ± 1.8* 18.7 ± 2.2* 15.3 ± 1.5 
0 
0 1 2 3 4 5 6 
Post-Exercise 13-HODE + 9-HODE (MSI) 
Fig. 5. Scatterplot relationships between at the postexercise time point for 
Values are means ± SE. IL, interleukin; TNF-ex, tumor necrosis factor-ex; 
MCP-1, monocyte chemoattractant protein-1; GCSF, granulocyte colony- 
stimulating factor. *P < 0.01 vs. preexercise. 
13-HODE + 9-HODE and arachidonate (r = 0.77, P < 0.001) (A), 12,13- 
DiHOME (r = 0.60, P = 0.006) (B), and F2-isoprostanes (r = 0.75, P < 
1.1) (C). MSI, median scaled intensity. 
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Plasma linoleate increased 3.7-fold postexercise in concert 
with other fatty acids in the conversion pathway, indicating a 
high degree of mobilization and availability. 
Linoleic acid is the predominant PUFA in the diet and 
adipose tissue stores and can be metabolized by cyclooxygen- 
ase, lipoxygenase, and P450 enzymes (32). 13-HODE + 9-
HODE are monohydroxy lipoxygenation products and the 
most widely distributed of linoleic acid metabolites (17, 32). 
The HODEs are secreted by a variety of cells including 
macrophages, endothelial cells, platelets, and smooth muscle 
cells, and exert biological and signaling activities as PPAR and 
GPR132 ligands (12, 21, 28, 37). Cell injury activates lipoxy- 
genases and may be one pathway through which intensive 
exercise increases production of HODES (33). Several cell 
culture studies indicate that HODES induce pro-inflammatory 
responses including generation of inflammatory cytokines such 
as IL-113 and IL-8 (16, 35), chemotactic activity of neutrophils 
(10), and stimulation of NF-KB activity (24). The data from 
this study, however, do not support that HODES are related to 
inflammatory cytokines within an exercise context despite 
similar patterns of change over time and peaking immediately 
postexercise. 
Isoprostanes are prostaglandin-like compounds produced by 
the free radical catalyzed peroxidation of arachidonic acid 
independent of cyclooxygenase (22, 30). A specific class of 
isoprostanes, the F2-IsoP, are an accurate indicator of in vivo 
oxidant stress and have been related to a variety of human 
disorders (30). The tight linkage between postexercise levels of 
13-HODE + 9-HODE and F2-IsoP is a novel finding from this 
study. Plasma concentrations of F2-IsoP are much lower than 
13-HODE + 9-HODE (39). Linoleate is the most abundant 
fatty acid in atherosclerotic plaques, and high levels of HODEs 
accumulate in the low-density lipoprotein (LDL) and plaque of 
patients with atherosclerosis compared with healthy controls 
(14). Similar to F2-IsoP, the HODEs are stable lipid peroxida- 
tion products that are elevated in diseased individuals and can 
be lowered through positive lifestyle changes (2, 3, 7, 25, 29, 
37). The data from this study support the use of 13-HODE + 
9-HODE as biomarkers of oxidative stress during exercise 
trials. 
Postexercise 13-HODE + 9-HODE was significantly corre- 
lated with 12,13-DiHOME, another derivative of linoleic acid 
diol. 12,13-DiHOME is produced via the oxidation of the 
isoleukotoxin 12,13-epoxyoctadecenoic acid (12,13-EpOME). 
Both 12,13-DiHOME and 12,13-EpOME are PPAR-'Y ligands 
with potentially wide-ranging effects. In addition to its role as 
a PPAR ligand, 12,13-DiHOME exerts toxic and oxidative 
effects, inhibits mitochondrial function, stimulates neutrophil 
chemotactic activity, and suppresses neutrophil respiratory 
burst activity (5, 31, 36, 38). 
 
Perspectives and Significance 
We recently reported that a 3-day period of intensified 
training elicited large changes in the human serum metabolome 
of runners (20). Athletes ran for 2.5 h/day on treadmills at 
~70%  V̇ O2max   for  3  days  in  a  row,  with  blood  samples 
collected preexercise and immediately and 14 h postexercise. 
Immediately after the 3-day exercise period, significant two- 
fold or higher increases in 75 metabolites were measured, with 
all but 22 of these metabolites related to lipid/carnitine metab- 
olism. We reported a fivefold postexercise increase in plasma 
13-HODE + 9-HODE, with levels returning to preexercise 
levels within 14-h recovery (20). Although this was the first 
published information on the acute increase in plasma 13- 
HODE + 9-HODE following intensive exercise, other inves- 
tigators using disease models had reported that higher HODE 
concentrations were excellent indicators of oxidative stress and 
should be considered in future studies because they were much 
more abundant than F2-isoprostanes (37, 39). A major objec- 
tive in the current study was to determine whether 13-HODE + 
9-HODE could be related to F2-isoprostanes within an exercise 
context, and this was established. In this study, cyclists com- 
pleting a 75-km time trial experienced twofold or higher 
increases in 80 metabolites, including linoleate and other fatty 
acids in the conversion pathway and the oxidized derivatives 
13-HODE + 9-HODE. Although 13-HODE + 9-HODE play 
proinflammatory roles under certain conditions, no relationship 
to postexercise increases in six cytokines was established in 
this study. The 3.1-fold postexercise increase in HODEs was 
significantly correlated with F2-IsoP, supporting the inclusion 
of HODEs as a stable oxidative stress biomarker in future 
exercise trials. 
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